Intrinsiqq
Immunovant Inc. logo

Immunovant Inc. Insider Trading

IMVT

Compare
Last 12 months

Insiders sold $16.3M and bought nothing on the open market.

9% of the selling was scheduled in advance under 10b5-1 plans. Director Andrew J. Fromkin sold $7.44M on May 28, 75% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2022.

Net open-market
−$16.3M
0 buys · 41 sales
Under a 10b5-1 plan
9%
of the value sold
Insiders who bought / sold
0 / 9
executives and directors
Last open-market buy
Sep 2022
Sep 30, 2022

Get an email when IMVT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 1110b5-1 plan
    Atul Pande
    Director · sold 3,000 at $36.00
    108K
    2.1% of stake
  • Oct 28No plan
    Tiago Girao
    Chief Financial Officer · sold 6,606 at $28.50
    188K
    2.7% of stake
  • Oct 21No plan
    Jay S Stout
    Chief Technology Officer · sold 2,595 at $28.94
    75K
    1.3% of stake
  • Oct 7No plan
    Jay S Stout
    Chief Technology Officer · sold 3,809 at avg $32.06
    122K
    1.9% of stake
  • Oct 7No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 1,327 at $32.06
    43K
    0.8% of stake
  • Oct 7No plan
    Melanie Gloria
    Chief Operating Officer · sold 2,241 at $32.06
    72K
    1.0% of stake
  • Oct 2No plan
    Eric Venker
    Chief Executive Officer · sold 3,506 at $34.11
    120K
    1.3% of stake
  • Sep 23No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 2,846 at $36.36
    103K
    1.6% of stake
  • Aug 2810b5-1 plan
    Atul Pande
    Director · sold 1,500 at $43.27
    65K
    1.1% of stake
  • Aug 20No plan
    Melanie Gloria
    Chief Operating Officer · sold 3,056 at $44.16
    135K
    1.4% of stake
  • Jul 2410b5-1 plan
    Atul Pande
    Director · sold 1,500 at $39.80
    60K
    1.1% of stake
  • Jul 23No plan
    Jay S Stout
    Chief Technology Officer · sold 2,857 at $38.69
    111K
    1.4% of stake
  • Jul 23No plan
    Tiago Girao
    Chief Financial Officer · sold 6,798 at $38.69
    263K
    2.7% of stake
  • Jul 8No plan
    Melanie Gloria
    Chief Operating Officer · sold 2,036 at avg $39.55
    81K
    0.9% of stake
  • Jul 8No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 1,206 at avg $39.55
    48K
    0.7% of stake
  • Jul 8No plan
    Jay S Stout
    Chief Technology Officer · sold 3,487 at avg $39.55
    138K
    1.6% of stake
  • Jul 2No plan
    Eric Venker
    Chief Executive Officer · sold 3,092 at $38.48
    119K
    1.2% of stake
  • Jun 26No plan
    Melanie Gloria
    Chief Operating Officer · sold 17,714 at avg $38.31
    679K
    7.3% of stake
  • Jun 26No plan
    Jay S Stout
    Chief Technology Officer · sold 40,000 at avg $38.31
    $1.53M
    16% of stake
  • Jun 26No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 17,824 at avg $38.31
    683K
    9.0% of stake
  • Jun 26No plan
    Tiago Girao
    Chief Financial Officer · sold 10,000 at $38.46
    385K
    3.9% of stake
  • Jun 2610b5-1 plan
    Atul Pande
    Director · sold 1,500 at $38.01
    57K
    1.1% of stake
  • Jun 18No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 2,634 at $35.39
    93K
    1.4% of stake
  • Jun 1510b5-1 plan
    Atul Pande
    Director · sold 1,500 at $34.02
    51K
    1.1% of stake
  • May 28No plan
    Andrew J. Fromkin
    Director · sold 221,951 at avg $33.51
    $7.44M
    75% of stake
  • May 20No plan
    Melanie Gloria
    Chief Operating Officer · sold 3,115 at avg $32.45
    101K
    1.3% of stake
  • May 2010b5-1 plan
    Atul Pande
    Director · sold 6,000 at $32.00
    192K
    4.2% of stake
  • May 110b5-1 plan
    Robert Graham Susman
    Director · sold 2,502 at $27.17
    68K
    6.4% of stake
  • Apr 23No plan
    Tiago Girao
    Chief Financial Officer · sold 25,760 at $29.62
    763K
    9.4% of stake
  • Apr 23No plan
    Jay S Stout
    Chief Technology Officer · sold 2,754 at $29.62
    82K
    1.1% of stake
  • Apr 8No plan
    Melanie Gloria
    Chief Operating Officer · sold 8,722 at $24.83
    217K
    3.4% of stake
  • Apr 8No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 5,165 at $24.83
    128K
    2.7% of stake
  • Apr 8No plan
    Jay S Stout
    Chief Technology Officer · sold 10,132 at avg $24.83
    252K
    3.8% of stake
  • Apr 2No plan
    Eric Venker
    Chief Executive Officer · sold 14,229 at avg $24.10
    343K
    42% of stake
  • Mar 18No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 2,877 at $24.97
    72K
    1.9% of stake
  • Feb 25No plan
    Melanie Gloria
    Chief Operating Officer · sold 3,238 at avg $27.85
    90K
    1.9% of stake
  • Jan 21No plan
    Jay S Stout
    Chief Technology Officer · sold 1,977 at $26.03
    51K
    1.0% of stake
  • Jan 7No plan
    Jay S Stout
    Chief Technology Officer · sold 1,203 at avg $26.53
    32K
    0.6% of stake
  • Dec 18, 2025No plan
    Christopher Van Tuyl
    Chief Legal Officer · sold 10,813 at avg $26.91
    291K
    6.7% of stake
  • Dec 12, 2025
    Roivant Sciences Ltd.
    Large holder · bought 16,666,666 at $21.00
    $350M
    17% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IMVT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IMVT

CompareIntrinsic value
CELZCreative Medical Technology Holdings Inc.
$0.40-8.14%10
VCELVericel Corporation
$57.52-1.27%65
IOVAIovance Biotherapeutics, Inc.
$6.90-5.61%10
CGONCG Oncology, Inc.
$79.47-2.97%40
TECHBio-Techne Corporation
$72.67-0.04%41
MRNAModerna, Inc.
$195.00-2.17%13
HALOHalozyme Therapeutics Inc.
$91.35-1.82%70
SCLXScilex Holding Company
$0.57-12.95%0

Held by ETFs

IMVT is in 51 US ETFs. The largest of them, with IMVT's weight in each:

Spot a number that looks wrong? Check it in IMVT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing IMVT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.